Takeda Pharmaceutical Co. Ltd.

In News

German Pharma Co. Says Takeda's ADHD Drug IP Isn't Valid - Law360

Law360 - Nov 12, 2025

Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings Report Preview: What To Look For - Yahoo Finance

Yahoo Finance - Oct 29, 2025

China's Innovent signs cancer therapy deal with Japan's Takeda - Reuters

Reuters - Oct 22, 2025

Takeda’s mezagitamab shows lasting kidney function in IgA nephropathy - BioWorld MedTech

BioWorld MedTech - Nov 11, 2025

Takeda Inks Deal With China’s Innovent to Develop Cancer Drugs - Bloomberg.com

Bloomberg.com - Oct 21, 2025

Takeda Pharmaceutical Co Ltd expected to post earnings of JPY33.80 a share - Earnings Preview - TradingView

TradingView - Oct 27, 2025

Innovent Strikes $11.4 Billion Cancer Drug Deal With Takeda - Caixin Global

Caixin Global - Oct 24, 2025

ANTITRUST—N.D. Cal.: Discovery will continue in Dexilant ‘pay-for-delay' suit (Oct 20, 2025) - VitalLaw.com

VitalLaw.com - Oct 20, 2025

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise - Seeking Alpha

Seeking Alpha - May 11, 2025

Takeda Expects Limited Exposure To US-China Tariffs - Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga

Benzinga - May 08, 2025

Takeda Pharmaceutical Co Ltd (TKPHF) Q1 2026 Earnings Call Highlights: Navigating Challenges ... - Yahoo Finance

Yahoo Finance - Jul 31, 2025

Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets - BioWorld MedTech

BioWorld MedTech - Oct 28, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment